Abstract Despite advances in neurosurgical technology and techniques, the survival rate of GBM patients has remained relatively unchanged. The main treatments for GBM are associated with difficulties resulting from incomplete tumor resection and recurrence. In such situations, Photodynamic Therapy (PDT) is increasingly popular as an advanced therapeutic strategy, characterized by fewer side effects, minimal toxicity, and more controlled treatment. 5-aminolevulinic acid hydrochloride, (5-ALA HCl) has been used for years as a photosensitizing drug for the intraoperative visualization of GBM tumor tissue, enabling a more complete tumor resection. We demonstrated that, after such fluorescence-guided surgery, a laser light of specific 635 nm wavelength can additionally induce specific tumor cell death via the production of reactive oxygen species. This 5-ALA HCl–based PDT provides an antitumor effect within the tumor resection margins where recurrences occur in almost all patients. After performing pilot studies in over 20 patients with primary GBM, leading to positive safety and survival signals, we designed a new drug-device combination for this specific PDT procedure. It consists of Pentalafen ®, 5-ALA HCl administered orally to the patient before surgery, combined to Heliance®, a balloon device, inflated intraoperatively into the resection cavity, and connected to a controller (laser system) via an optical fiber to produce the light that illuminates the resection margins. A dedicated algorithm enables the duration of the illumination to be automatically computed from the tumor volume. This procedure adds an average of 30 minutes to the neurosurgery and can thus be fully integrated into the standard of care for primary GBM. This new drug-device combination is currently evaluated in a US phase 1 trial (NCT05736406) evaluating the feasibility of different light regimen treatments with the aim of delaying GBM recurrence and improving overall survival. If data is confirmed, it could be applicable to other CNS and solid tumors.
Read full abstract